{
    "organizations": [],
    "uuid": "8988fc992c0e067a26597e16df03c6413454e903",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/01/29/globe-newswire-gw-pharmaceuticals-to-report-q1-financial-results-and-host-conference-call-on-5-february-2018.html",
    "ord_in_thread": 0,
    "title": "GW Pharmaceuticals to Report Q1 Financial Results and Host Conference Call on 5 February, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "LONDON, Jan. 29, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2018 its first quarter financial results for the period ending 31 December, 2017. GW will also host a conference call the same day at 4:30 p.m. EST. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website ( www.gwpharm.com ) shortly after the call.\nAbout GW Pharmaceuticals plc\nFounded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted an NDA to the FDA for the adjunctive treatment of LGS and Dravet syndrome. The Company continues to evaluate Epidiolex in additional epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex ® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for gliobastoma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com .\nEnquiries:\nGW Pharmaceuticals plc Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570\nSource: GW Pharmaceuticals plc",
    "published": "2018-01-29T21:00:00.000+02:00",
    "crawled": "2018-01-29T20:45:03.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "london",
        "globe",
        "newswire",
        "gw",
        "pharmaceutical",
        "plc",
        "nasdaq",
        "gwph",
        "gw",
        "company",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "commercializing",
        "novel",
        "therapeutic",
        "proprietary",
        "cannabinoid",
        "product",
        "platform",
        "announce",
        "february",
        "first",
        "quarter",
        "financial",
        "result",
        "period",
        "ending",
        "december",
        "gw",
        "also",
        "host",
        "conference",
        "call",
        "day",
        "est",
        "conference",
        "call",
        "information",
        "provided",
        "financial",
        "result",
        "press",
        "release",
        "replay",
        "call",
        "also",
        "available",
        "company",
        "website",
        "shortly",
        "call",
        "gw",
        "pharmaceutical",
        "plc",
        "founded",
        "gw",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "commercializing",
        "novel",
        "therapeutic",
        "proprietary",
        "cannabinoid",
        "product",
        "platform",
        "broad",
        "range",
        "disease",
        "area",
        "gw",
        "along",
        "subsidiary",
        "greenwich",
        "bioscience",
        "advancing",
        "orphan",
        "drug",
        "program",
        "field",
        "childhood",
        "epilepsy",
        "focus",
        "epidiolex",
        "cannabidiol",
        "gw",
        "submitted",
        "nda",
        "fda",
        "adjunctive",
        "treatment",
        "lgs",
        "dravet",
        "syndrome",
        "company",
        "continues",
        "evaluate",
        "epidiolex",
        "additional",
        "epilepsy",
        "condition",
        "currently",
        "ongoing",
        "clinical",
        "trial",
        "tuberous",
        "sclerosis",
        "complex",
        "infantile",
        "spasm",
        "gw",
        "commercialized",
        "world",
        "first",
        "cannabinoid",
        "prescription",
        "drug",
        "sativex",
        "nabiximols",
        "approved",
        "treatment",
        "spasticity",
        "due",
        "multiple",
        "sclerosis",
        "numerous",
        "country",
        "outside",
        "united",
        "state",
        "company",
        "deep",
        "pipeline",
        "additional",
        "cannabinoid",
        "product",
        "candidate",
        "includes",
        "compound",
        "phase",
        "trial",
        "gliobastoma",
        "schizophrenia",
        "epilepsy",
        "information",
        "please",
        "visit",
        "enquiry",
        "gw",
        "pharmaceutical",
        "plc",
        "stephen",
        "schultz",
        "vp",
        "investor",
        "relation",
        "source",
        "gw",
        "pharmaceutical",
        "plc"
    ]
}